Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL4647048 | 0.83 | PTPN1 (0.50) | PTPN1MAOAMAOBSNRNP200PDE3B | |
| SCHEMBL4647040 | 0.83 | PTPN1 (0.50) | PTPN1ADAM17MMP9MAOAMAOB | |
| SCHEMBL22412482 | 0.82 | PTPN1 (0.63) | PTPN1PTPN2MCHR1KCNH2 | |
| SCHEMBL22412375 | 0.82 | PTPN1 (0.55) | PTPN1PTPN2MCHR1KCNH2 | |
| SCHEMBL4646574 | 0.81 | PTPN1 (0.48) | PTPN1ADAM17MMP1PTPN2GRM2 | |
| SCHEMBL2933961 | 0.81 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL3917674 | 0.80 | PTPN1 (0.44) | PTPN1MAOAMAOB | |
| SCHEMBL4646906 | 0.79 | PTPN1 (0.53) | PTPN1MAOAMAOBPTPN2SNRNP200 | |
| SCHEMBL4643306 | 0.79 | PTPN1 (0.53) | PTPN1PTPN2 | |
| Potassium SCHEMBL629775 | 0.78 | PTPN1 (0.51) | PTPN1MAOAMAOBPTPN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1960377-A1 | l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067614-A1 | l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | PTPN1 10/4885ADAM17 3239/4885MMP9 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.